Sugi Predict

Sugi Predict / Compounds / SCHEMBL608749

SCHEMBL608749

SCHEMBL608749

COc1cc(Br)cnc1Cl

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 4/20 0.42
▸ CHRNA4 P43681 4/20 0.42
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CHRNB4 P30926 2/20 0.38
▸ CHRNA3 P32297 2/20 0.38
▸ CHRNA7 P36544 2/20 0.38
▸ NQO2 P16083 2/20 0.36
▸ SHMT2 P34897 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30366269 1.00 CHRNB2 (0.42) CHRNB2CHRNA4MEN1KMT2APOLB
SCHEMBL30499138 0.81 EGFR (0.33) MEN1KMT2APOLB
SCHEMBL2147358 0.81 EGFR (0.33) MEN1KMT2APOLB
SCHEMBL26170410 0.81 HTT (0.35) KMT2A
SCHEMBL189068 0.80 GRM5 (0.44) MEN1KMT2APOLBALDH1A1SMN1; SMN2
SCHEMBL29812510 0.80 PLAU (0.42) POLBALDH1A1KDM4E
SCHEMBL17593337 0.80 PLAU (0.42) POLBALDH1A1KDM4E
SCHEMBL28850186 0.79 KMT2A (0.39) MEN1KMT2APOLB
SCHEMBL30866857 0.79 MET (0.41) —
SCHEMBL21512505 0.79 MET (0.41) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612407-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist BEONE MEDICINES I GMBH (CH) 2026-04-28 — — US disclosed
US-12577229-B2 Substituted {5-methoxy-6-[(5-methoxypyridin-2-yl)methoxy]pyridin-3-yl} methyl compounds as CSF-1R inhibitors ELI LILLY AND COMPANY (US) 2026-03-17 — — US disclosed
US-20250360145-A1 CSF-1R INHIBITORS AND USES THEREOF MYROBALAN THERAPEUTICS INC (US) 2025-11-27 — — US disclosed
EP-4605089-A1 COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K Mekanistic Therapeutics LLC (US) 2025-08-27 — — EP disclosed
EP-4146641-B1 SUBSTITUTED {5-METHOXY-6-[(5-METHOXYPYRIDIN-2-YL)METHOXY]PYRIDIN-3-YL}METHYL COMPOUNDS AS CSF-1R INHIBITORS LILLY CO ELI (US) 2025-06-11 — — EP disclosed
CN-119998271-A Pyridone compound and preparation method and application thereof 深圳信立泰药业股份有限公司 2025-05-13 — — CN disclosed
EP-4539933-A1 CSF-1R INHIBITORS AND USES THEREOF Myrobalan Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
CN-113423708-B Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists 百济神州有限公司 2025-04-22 — — CN disclosed
US-12275723-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2025-04-15 — — US disclosed
CN-119790038-A CSF-1R inhibitors and uses thereof 迈巴制药公司 2025-04-08 — — CN disclosed
CN-1440410-A Diazabicyclic central nervous system active agents ABBOTT LAB (US) 2003-09-03 — — CN disclosed
EP-1284976-A2 DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS Abbott Laboratories (US) 2003-02-26 — — EP disclosed
CN-1361774-A Heterocyclic substituted amino nitrogen heterocycles as central nervous system medicaments ABBOTT INC (US) 2002-07-31 — — CN disclosed
CN-1345320-A Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands ABBOTT LAB (US) 2002-04-17 — — CN disclosed
US-20020019388-A1 Diazabicyclic central nervous system active agents ABBVIE INC. 2002-02-14 — — US disclosed
EP-1178982-A1 HETEROCYCLIC SUBSTITUTED AMINOAZACYCLES USEFUL AS CENTRAL NERVOUS SYSTEM AGENTS ABBOTT LABORATORIES (US) 2002-02-13 — — EP disclosed
WO-2001081347-A2 DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS ABBOTT LABORATORIES (US) 2001-11-01 — — WO disclosed
EP-1147112-A1 DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2001-10-24 — — EP disclosed
WO-2000071534-A1 HETEROCYCLIC SUBSTITUTED AMINOAZACYCLES USEFUL AS CENTRAL NERVOUS SYSTEM AGENTS ABBOTT LABORATORIES (US) 2000-11-30 — — WO disclosed
WO-2000044755-A1 DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2000-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12275723-B2 Compounds and uses thereof NLN, ACHE, CLN6 CHRNB2 365/4885CHRNA4 190/4885MEN1 1807/4885
US-12612407-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist TLR7, TLR8, TLR1 CHRNB2 534/4885CHRNA4 302/4885MEN1 4551/4885
US-12577229-B2 Substituted {5-methoxy-6-[(5-methoxypyridin-2-yl)methoxy]pyridin-3-yl} methyl compounds as CSF-1R inhibitors CSF1R, CSF3R, AGER CHRNB2 446/4885CHRNA4 477/4885MEN1 1721/4885
US-20020019388-A1 Diazabicyclic central nervous system active agents GAP43, GABRE, CHRNA6 CHRNB2 11/4885CHRNA4 8/4885MEN1 428/4885
US-20250360145-A1 CSF-1R INHIBITORS AND USES THEREOF CSF1R, CSF3R, IL1RN CHRNB2 1912/4885CHRNA4 3114/4885MEN1 1411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.